Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of SHR-1819 in healthy subjects
NCT04772365Phase 1Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Mar 2021
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in asthma comparing SHR-1819 Group with Placebo Group (2 arms). Primary endpoint: Adverse events at 13 weeks. Started Mar 2021; status: completed.
02
Drugs
SHR-1819
03
Conditions
asthma
Beyond the preview
Go deeper on NCT04772365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04772365.